ICER revises its value assessment framework, but is it enough?

The value assessment landscape in the US is evolving rapidly, fueled by many changes including the forthcoming implementation of the Inflation Reduction Act. With a greater emphasis on patient-centeredness, health equity, and stakeholder engagement, value assessors are looking to develop more robust and transparent methods for measuring value, leading to better-informed decision-making about prescription drugs. Without a centralized health technology assessment (HTA) body in the US, policymakers and payers are reliant on third-party value assessors to inform coverage decisions. By providing independent and transparent assessments of the cost effectiveness and value of healthcare interventions, the Institute for Clinical and Economic...